Hepatotropic viruses induced hepatitis progresses much faster and causes more liver-
related health problems in people co-infected with human immunodeficiency virus (HIV) …

Hepatitis C virus (HCV) genotype 4 is highly heterogeneous. HCV subtype 4r has been
suggested to be less responsive to direct‐acting antiviral (DAA) drug treatment than other …

Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver
cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been …

Conclusions: Non-liver non-AIDS–related events were the leading causes of morbidity and
mortality after direct-acting antiviral cure among coinfected patients with advanced …

The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV
treatment, with most recent trials demonstrating high efficacy rates (> 90%) across all …

Objectives: We analysed hepatitis C virus (HCV) reinfection among participants in a
prospective registry of HIV/HCV-coinfected patients treated with all-oral direct-acting …

Background Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection is
associated with accelerated progression to cirrhosis, end-stage liver disease, and liver …

Objectives We assessed the prevalence of anti‐hepatitis C virus (HCV) antibodies and
active HCV infection (HCV‐RNA‐positive) in people living with HIV (PLWH) in Spain in 2019 …

Hepatitis C virus (HCV) cure after all-oral direct-acting antiviral (DAA) therapy greatly
improves the liver and immune system. We aimed to assess the impact of this HCV …

Background Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have
facilitated sustained virologic response (SVR) rates> 90% in clinical studies. Yet, real life …